The Toronto-based firm targets $125 million USD for the Women’s and Children’s Health Technology Fund II by the second half of 2027. Limited partners include KfW, Skoll Foundation, Capricorn Investment Group, Ceniarth, Equality Fund, RockCreek Group, and Wire Group, with KfW providing concessionary capital.
The fund will write Series A and B cheques of $2 million to $5 million USD into about a dozen biotech, medical device, diagnostics, and other healthtech companies with global commercial potential. CBIV has not yet invested in a Canadian company but hopes to find opportunities in the new fund.